162 related articles for article (PubMed ID: 16522526)
1. Effect of a combined oral contraceptive containing 20 microg ethinyl estradiol and 75 microg gestodene on hemostatic parameters.
Aldrighi JM; De Campos LS; Eluf Gebara OC; Petta CA; Bahamondes L
Gynecol Endocrinol; 2006 Jan; 22(1):1-4. PubMed ID: 16522526
[TBL] [Abstract][Full Text] [Related]
2. Effects of two oral contraceptives, containing 30 or 20 microg of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women.
Ferreira AC; Montes MB; Franceschini SA; Toloi MR
Int J Fertil Womens Med; 2001; 46(5):265-70. PubMed ID: 11720199
[TBL] [Abstract][Full Text] [Related]
3. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
[TBL] [Abstract][Full Text] [Related]
4. Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters.
Wiegratz I; Stahlberg S; Manthey T; Sänger N; Mittmann K; Lange E; Mellinger U; Kuhl H
Contraception; 2008 Nov; 78(5):384-91. PubMed ID: 18929735
[TBL] [Abstract][Full Text] [Related]
5. [Hemostatic balance during treatment with the newest contraceptives].
Petersen KR; Skouby SO; Sidelmann J; Jespersen J
Ugeskr Laeger; 1994 Jan; 156(2):187-90. PubMed ID: 8296409
[TBL] [Abstract][Full Text] [Related]
6. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure.
Yildizhan R; Yildizhan B; Adali E; Yoruk P; Birol F; Suer N
Arch Gynecol Obstet; 2009 Aug; 280(2):255-61. PubMed ID: 19125264
[TBL] [Abstract][Full Text] [Related]
7. [The effect of two low dose oral contraceptive with gestodene on the systems of natural inhibitors of coagulation].
Uchikova E; Terzhumanov R; Milchev N; Iacheva T
Akush Ginekol (Sofiia); 2004; 43(6):19-23. PubMed ID: 15669648
[TBL] [Abstract][Full Text] [Related]
8. Body weight change during use of a monophasic oral contraceptive containing 20 microg ethinylestradiol and 75 microg gestodene with a comparison of the women who completed versus those who prematurely discontinued intake.
Endrikat J; Gerlinger C; Cronin M; Wessel J; Ruebig A; Rosenbaum P; Düsterberg B
Eur J Contracept Reprod Health Care; 2001 Dec; 6(4):199-204. PubMed ID: 11848649
[TBL] [Abstract][Full Text] [Related]
9. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol.
Kluft C; Endrikat J; Mulder SM; Gerlinger C; Heithecker R
Contraception; 2006 Apr; 73(4):336-43. PubMed ID: 16531162
[TBL] [Abstract][Full Text] [Related]
10. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
[TBL] [Abstract][Full Text] [Related]
11. A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 30 microg ethinyl estradiol and 75 microg gestodene on hemostatic variables, lipids, and carbohydrate metabolism.
Endrikat J; Klipping C; Gerlinger C; Ruebig A; Schmidt W; Holler T; Düsterberg B
Contraception; 2001 Oct; 64(4):235-41. PubMed ID: 11747873
[TBL] [Abstract][Full Text] [Related]
12. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
Tans G; Curvers J; Middeldorp S; Thomassen MC; Meijers JC; Prins MH; Bouma BN; Büller HR; Rosing J
Thromb Haemost; 2000 Jul; 84(1):15-21. PubMed ID: 10928463
[TBL] [Abstract][Full Text] [Related]
13. Effect of four oral contraceptives on hemostatic parameters.
Wiegratz I; Lee JH; Kutschera E; Winkler UH; Kuhl H
Contraception; 2004 Aug; 70(2):97-106. PubMed ID: 15288212
[TBL] [Abstract][Full Text] [Related]
14. Effect of two low-dose gestodene containing monophasic oral contraceptives on hemostasis in Bulgarian women.
Uchikova E; Pehlivanov B
Expert Opin Pharmacother; 2008 Aug; 9(11):1839-44. PubMed ID: 18627323
[TBL] [Abstract][Full Text] [Related]
15. Effects of two combined monophasic and triphasic ethinylestradiol/gestodene oral contraceptives on natural inhibitors and other hemostatic variables.
Creatsas G; Kontopoulou-Griva I; Deligeoroglou E; Digenopoulou L; Tsangaris A; Kallipolitis G; Milingos S; Michalas S
Eur J Contracept Reprod Health Care; 1997 Mar; 2(1):31-8. PubMed ID: 9678107
[TBL] [Abstract][Full Text] [Related]
16. Blood pressure stability in a normotensive population during intake of a monophasic oral contraceptive containing 20 microg ethinylestradiol and 75 g gestodene.
Endrikat J; Gerlinger C; Cronin M; Ruebig A; Schmidt W; Düsterberg B
Eur J Contracept Reprod Health Care; 2001 Sep; 6(3):159-66. PubMed ID: 11763980
[TBL] [Abstract][Full Text] [Related]
17. Effects of an oral contraceptive containing drospirenone on bone turnover and bone mineral density.
Nappi C; Di Spiezio Sardo A; Greco E; Tommaselli GA; Giordano E; Guida M
Obstet Gynecol; 2005 Jan; 105(1):53-60. PubMed ID: 15625142
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel.
Winkler UH; Daume E; Sudik R; Oberhoff C; Bier U; Hallmann C; Andreas JO; Schindler AE
Eur J Contracept Reprod Health Care; 1999 Sep; 4(3):145-54. PubMed ID: 10574640
[TBL] [Abstract][Full Text] [Related]
19. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism.
Klipping C; Marr J
Contraception; 2005 Jun; 71(6):409-16. PubMed ID: 15914128
[TBL] [Abstract][Full Text] [Related]
20. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 microg) and gestodene (75 microg).
Machado RB; Fabrini P; Cruz AM; Maia E; da Cunha Bastos A
Contraception; 2004 Nov; 70(5):365-70. PubMed ID: 15504374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
